Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Trial Profile

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab
  • Indications Biliary cancer; Head and neck cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 May 2019 Results assessing tolerability and efficacy of durvalumab in japanese population published in the Cancer Science
    • 08 Mar 2019 Planned End Date changed from 29 Mar 2019 to 31 Mar 2020.
    • 19 Jan 2019 Results assesssing the safety and tolerability of durvalumab with or without tremelimumab in patients with biliary tract cancer (n=107) presented at the 2019 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top